Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Integrated analysis of pooled data from double-blind phase III clinical studies

Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Integrated analysis of pooled data from double-blind phase III clinical studies

Autor Gil-Nagel, Antonio Google Scholar
Elger, Christian Google Scholar
Ben-Menachem, Elinor Google Scholar
Halasz, Peter Google Scholar
Lopes-Lima, Jose Google Scholar
Gabbai, Alberto A. Autor UNIFESP Google Scholar
Nunes, Teresa Google Scholar
Falcao, Amilcar Google Scholar
Almeida, Luis Google Scholar
Soares-da-Silva, Patricio Google Scholar
Instituição Hosp Ruber Int
Univ Bonn
Sahlgrens Univ Hosp
Expt Med Res Inst
Univ Porto
Universidade Federal de São Paulo (UNIFESP)
BIAL Portela & Ca SA
4Health Ltd
Univ Coimbra
Univ Aveiro
Resumo Purpose: To evaluate the efficacy and safety profile of eslicarbazepine acetate (ESL) added to stable antiepileptic therapy in adults with partial-onset seizures. Methods: Data from 1,049 patients enrolled from 125 centers, in 23 countries, in three phase III double-blind, randomized, placebo-controlled studies were pooled and analyzed. Following a 2-week titration period, ESL was administered at 400 mg, 800 mg, and 1,200 mg once-daily doses for 12 weeks. Key Findings: Seizure frequency was significantly reduced with ESL 800 mg (p < 0.0001) and 1,200 mg (p < 0.0001) compared to placebo. Median relative reduction in seizure frequency was, respectively, 35% and 39% (placebo 15%) and responder rate was 36% and 44% (placebo 22%). ESL was more efficacious than placebo regardless of gender, geographic region, epilepsy duration, age at time of diagnosis, seizure type, and number and type of concomitant antiepileptic drugs (AEDs). Incidence of adverse events (AEs) and AEs leading to discontinuation were dose dependent. AEs occurred mainly during the first weeks of treatment, with no difference between groups after 6 weeks. Most common AEs (>10% patients) were dizziness, somnolence, and headache. the incidence of AEs in ESL groups compared to placebo was generally consistent among different subpopulations. Significance: Once-daily ESL 800 mg and 1,200 mg showed consistent results across all efficacy and safety end points. Results were independent of study population characteristics and type and number of concomitant AEDs.
Assunto Adjunctive therapy
Adults
Antiepileptic drugs
Eslicarbazepine acetate
Partial-onset seizures
Refractory epilepsy
Idioma Inglês
Financiador BIAL - Portela Co, SA
BIAL
Data 2013-01-01
Publicado em Epilepsia. Hoboken: Wiley-Blackwell, v. 54, n. 1, p. 98-107, 2013.
ISSN 0013-9580 (Sherpa/Romeo, fator de impacto)
Editor Wiley-Blackwell
Extensão 98-107
Fonte http://dx.doi.org/10.1111/j.1528-1167.2012.03605.x
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000313116500017
URI http://repositorio.unifesp.br/handle/11600/35667

Mostrar registro completo




Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)